ADGRE3

Across TCGA pan-cancer cohorts, ADGRE3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ADGRE3 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ADGRE3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADGRE3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUAD, SARC, and STAD are the cancer types where ADGRE3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.083	0.680	<.001	18	view →
SARC	OS	Median	All	0.156	0.767	.001	12	view →
STAD	OS	Median	IV	0.111	0.433	.002	3	view →
SKCM	DFS	Median	II,III,IV	0.885	0.658	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ADGRE3–LUAD (OS)

Open the LUAD breakdown →